 Erin Schenk
Concepts (190)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 27 | 2025 | 2526 | 3.520 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 19 | 2025 | 1081 | 3.200 |
Why?
| | Platinum | 1 | 2019 | 50 | 0.630 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 1692 | 0.590 |
Why?
| | ErbB Receptors | 6 | 2024 | 614 | 0.590 |
Why?
| | Tumor Microenvironment | 6 | 2022 | 674 | 0.540 |
Why?
| | Mutation | 6 | 2024 | 3958 | 0.490 |
Why?
| | Sarcoma | 1 | 2017 | 188 | 0.460 |
Why?
| | Neoplasm Staging | 5 | 2025 | 1389 | 0.450 |
Why?
| | Acrylamides | 2 | 2024 | 57 | 0.440 |
Why?
| | Biomarkers, Tumor | 8 | 2024 | 1276 | 0.440 |
Why?
| | Aniline Compounds | 2 | 2024 | 102 | 0.430 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 2 | 2024 | 267 | 0.400 |
Why?
| | Cytarabine | 1 | 2012 | 61 | 0.380 |
Why?
| | Protein Kinases | 1 | 2012 | 319 | 0.330 |
Why?
| | Receptor, ErbB-2 | 2 | 2024 | 341 | 0.320 |
Why?
| | Neoadjuvant Therapy | 2 | 2024 | 404 | 0.310 |
Why?
| | Immunotherapy | 4 | 2020 | 641 | 0.300 |
Why?
| | Protein Kinase Inhibitors | 4 | 2024 | 916 | 0.300 |
Why?
| | Pyrimidines | 4 | 2024 | 470 | 0.300 |
Why?
| | Cell Cycle Proteins | 1 | 2012 | 617 | 0.290 |
Why?
| | B7-H1 Antigen | 2 | 2020 | 217 | 0.260 |
Why?
| | Humans | 35 | 2025 | 137585 | 0.260 |
Why?
| | Neoplasms | 3 | 2021 | 2671 | 0.260 |
Why?
| | Antineoplastic Agents | 4 | 2024 | 2129 | 0.240 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2012 | 630 | 0.240 |
Why?
| | Pemetrexed | 1 | 2024 | 33 | 0.230 |
Why?
| | Cell Line, Tumor | 4 | 2024 | 3412 | 0.230 |
Why?
| | Zinc Finger Protein Gli2 | 1 | 2024 | 4 | 0.230 |
Why?
| | Oncogenes | 1 | 2024 | 116 | 0.210 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2024 | 75 | 0.210 |
Why?
| | Oncogene Addiction | 1 | 2023 | 5 | 0.200 |
Why?
| | Survival Rate | 4 | 2024 | 1972 | 0.200 |
Why?
| | Bevacizumab | 1 | 2023 | 138 | 0.190 |
Why?
| | Receptors, Purinergic P1 | 1 | 2021 | 26 | 0.180 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2024 | 289 | 0.170 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2024 | 539 | 0.170 |
Why?
| | Carbon Monoxide | 1 | 2020 | 81 | 0.170 |
Why?
| | Major Histocompatibility Complex | 1 | 2021 | 227 | 0.170 |
Why?
| | Benzimidazoles | 1 | 2021 | 170 | 0.170 |
Why?
| | Organophosphorus Compounds | 1 | 2020 | 78 | 0.160 |
Why?
| | Etoposide | 2 | 2019 | 158 | 0.160 |
Why?
| | Quinazolines | 1 | 2021 | 251 | 0.160 |
Why?
| | Aged, 80 and over | 5 | 2024 | 7635 | 0.160 |
Why?
| | Picornaviridae | 1 | 2019 | 18 | 0.160 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2023 | 434 | 0.160 |
Why?
| | Diagnostic Imaging | 1 | 2022 | 332 | 0.160 |
Why?
| | Adenosine | 1 | 2021 | 225 | 0.160 |
Why?
| | Proto-Oncogene Proteins | 1 | 2023 | 648 | 0.160 |
Why?
| | Carboplatin | 1 | 2019 | 144 | 0.150 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2020 | 367 | 0.150 |
Why?
| | Cisplatin | 2 | 2019 | 320 | 0.140 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2024 | 1396 | 0.140 |
Why?
| | Maximum Tolerated Dose | 2 | 2021 | 199 | 0.140 |
Why?
| | Adaptive Immunity | 1 | 2019 | 165 | 0.140 |
Why?
| | Aged | 8 | 2024 | 23961 | 0.140 |
Why?
| | Trans-Activators | 1 | 2020 | 398 | 0.140 |
Why?
| | Lymphocyte Count | 1 | 2017 | 148 | 0.130 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2019 | 190 | 0.130 |
Why?
| | Antigens, CD19 | 1 | 2017 | 123 | 0.130 |
Why?
| | Pancreatic Neoplasms | 1 | 2024 | 938 | 0.120 |
Why?
| | Complement Activation | 1 | 2019 | 415 | 0.120 |
Why?
| | Interferon-gamma | 1 | 2019 | 789 | 0.120 |
Why?
| | Middle Aged | 9 | 2024 | 33479 | 0.120 |
Why?
| | ROC Curve | 1 | 2017 | 554 | 0.120 |
Why?
| | Genomics | 1 | 2020 | 795 | 0.120 |
Why?
| | Male | 11 | 2024 | 67762 | 0.120 |
Why?
| | Nuclear Proteins | 1 | 2020 | 712 | 0.120 |
Why?
| | Influenza Vaccines | 1 | 2020 | 539 | 0.110 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2021 | 900 | 0.110 |
Why?
| | Double-Blind Method | 1 | 2019 | 1993 | 0.110 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2019 | 801 | 0.110 |
Why?
| | Monocytes | 1 | 2017 | 563 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2021 | 2057 | 0.110 |
Why?
| | Brain Neoplasms | 1 | 2023 | 1238 | 0.100 |
Why?
| | Female | 10 | 2024 | 73304 | 0.100 |
Why?
| | Bortezomib | 1 | 2013 | 54 | 0.100 |
Why?
| | Boronic Acids | 1 | 2013 | 37 | 0.100 |
Why?
| | Lactams, Macrocyclic | 1 | 2013 | 49 | 0.100 |
Why?
| | Benzoquinones | 1 | 2013 | 48 | 0.100 |
Why?
| | Immunohistochemistry | 3 | 2022 | 1738 | 0.100 |
Why?
| | Checkpoint Kinase 1 | 1 | 2012 | 30 | 0.100 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2012 | 66 | 0.100 |
Why?
| | Mass Screening | 1 | 2020 | 1287 | 0.100 |
Why?
| | Pyrazines | 1 | 2013 | 90 | 0.100 |
Why?
| | Cell Cycle Checkpoints | 1 | 2012 | 98 | 0.090 |
Why?
| | Molecular Chaperones | 3 | 2002 | 195 | 0.090 |
Why?
| | B7-1 Antigen | 2 | 2008 | 58 | 0.090 |
Why?
| | Medical Oncology | 2 | 2024 | 289 | 0.090 |
Why?
| | Indoles | 2 | 2024 | 412 | 0.090 |
Why?
| | Practice Guidelines as Topic | 3 | 2025 | 1587 | 0.080 |
Why?
| | Pyrazoles | 1 | 2012 | 423 | 0.080 |
Why?
| | Prospective Studies | 1 | 2020 | 7604 | 0.070 |
Why?
| | Interleukin-17 | 1 | 2008 | 119 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2024 | 1477 | 0.070 |
Why?
| | Forkhead Transcription Factors | 1 | 2008 | 191 | 0.070 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2020 | 249 | 0.070 |
Why?
| | T-Lymphocytes, Cytotoxic | 1 | 2007 | 173 | 0.060 |
Why?
| | Neoplasms, Experimental | 1 | 2007 | 176 | 0.060 |
Why?
| | Antibodies | 1 | 2008 | 410 | 0.060 |
Why?
| | Molecular Targeted Therapy | 2 | 2019 | 411 | 0.060 |
Why?
| | Immunoglobulin M | 1 | 2007 | 289 | 0.060 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2008 | 385 | 0.060 |
Why?
| | Flow Cytometry | 3 | 2022 | 1178 | 0.060 |
Why?
| | Antiporters | 2 | 2002 | 22 | 0.060 |
Why?
| | T-Lymphocyte Subsets | 1 | 2007 | 417 | 0.060 |
Why?
| | Cell Proliferation | 1 | 2012 | 2475 | 0.060 |
Why?
| | Retrospective Studies | 4 | 2024 | 15657 | 0.060 |
Why?
| | Immunoglobulins | 2 | 2002 | 171 | 0.060 |
Why?
| | Mice | 6 | 2024 | 17787 | 0.050 |
Why?
| | Treatment Outcome | 2 | 2023 | 10811 | 0.050 |
Why?
| | Prognosis | 2 | 2024 | 4030 | 0.050 |
Why?
| | Histocompatibility Antigens Class I | 2 | 2002 | 203 | 0.050 |
Why?
| | DNA Copy Number Variations | 1 | 2024 | 182 | 0.050 |
Why?
| | Apoptosis | 1 | 2012 | 2553 | 0.050 |
Why?
| | Lymphocyte Activation | 1 | 2007 | 1142 | 0.050 |
Why?
| | Adult | 5 | 2024 | 37929 | 0.050 |
Why?
| | Carcinogenesis | 1 | 2024 | 217 | 0.050 |
Why?
| | Autoimmunity | 1 | 2008 | 908 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2024 | 658 | 0.050 |
Why?
| | HLA-A Antigens | 1 | 2002 | 55 | 0.050 |
Why?
| | HLA-B Antigens | 1 | 2002 | 62 | 0.050 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2021 | 79 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2021 | 134 | 0.040 |
Why?
| | Cell Line | 3 | 2020 | 2847 | 0.040 |
Why?
| | Central Nervous System | 1 | 2023 | 258 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2022 | 499 | 0.040 |
Why?
| | Promoter Regions, Genetic | 1 | 2024 | 1250 | 0.040 |
Why?
| | Suppressor of Cytokine Signaling 1 Protein | 1 | 2019 | 12 | 0.040 |
Why?
| | Gene Amplification | 1 | 2019 | 104 | 0.040 |
Why?
| | Drug Administration Schedule | 1 | 2021 | 786 | 0.040 |
Why?
| | Chemokine CXCL9 | 1 | 2019 | 27 | 0.040 |
Why?
| | Complement C5a | 1 | 2019 | 71 | 0.040 |
Why?
| | Complement C3a | 1 | 2019 | 42 | 0.040 |
Why?
| | Animals | 6 | 2024 | 36940 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2020 | 4295 | 0.040 |
Why?
| | Mice, Transgenic | 1 | 2024 | 2167 | 0.040 |
Why?
| | Polymorphism, Genetic | 1 | 2002 | 660 | 0.040 |
Why?
| | Histones | 1 | 2024 | 636 | 0.040 |
Why?
| | Complement Inactivating Agents | 1 | 2019 | 63 | 0.040 |
Why?
| | Gene Silencing | 1 | 2019 | 195 | 0.040 |
Why?
| | Programmed Cell Death 1 Ligand 2 Protein | 2 | 2008 | 15 | 0.040 |
Why?
| | Transcription, Genetic | 1 | 2024 | 1457 | 0.030 |
Why?
| | Sequence Analysis, RNA | 1 | 2020 | 452 | 0.030 |
Why?
| | Single-Cell Analysis | 1 | 2020 | 313 | 0.030 |
Why?
| | Disease Progression | 1 | 2024 | 2757 | 0.030 |
Why?
| | Carcinoma, Small Cell | 1 | 1997 | 172 | 0.030 |
Why?
| | Interferon Type I | 1 | 1997 | 140 | 0.030 |
Why?
| | Ecosystem | 1 | 2020 | 596 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2020 | 804 | 0.030 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2019 | 683 | 0.030 |
Why?
| | Macrophages | 1 | 2020 | 1547 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2020 | 1996 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2023 | 3566 | 0.020 |
Why?
| | Membrane Transport Proteins | 2 | 2002 | 162 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2019 | 5131 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2020 | 5757 | 0.020 |
Why?
| | T-Cell Antigen Receptor Specificity | 1 | 2008 | 50 | 0.020 |
Why?
| | Perforin | 1 | 2007 | 19 | 0.020 |
Why?
| | Pore Forming Cytotoxic Proteins | 1 | 2007 | 16 | 0.020 |
Why?
| | Cell Communication | 1 | 2008 | 315 | 0.020 |
Why?
| | Immune Tolerance | 1 | 2008 | 363 | 0.020 |
Why?
| | Multiple Myeloma | 1 | 2008 | 252 | 0.010 |
Why?
| | Dendritic Cells | 1 | 2008 | 483 | 0.010 |
Why?
| | Membrane Glycoproteins | 1 | 2007 | 500 | 0.010 |
Why?
| | Vaccines | 1 | 2008 | 406 | 0.010 |
Why?
| | HLA-B15 Antigen | 1 | 2002 | 13 | 0.010 |
Why?
| | Histidine | 1 | 2002 | 64 | 0.010 |
Why?
| | Aspartic Acid | 1 | 2002 | 79 | 0.010 |
Why?
| | Glutamine | 1 | 2002 | 103 | 0.010 |
Why?
| | Substrate Specificity | 1 | 2002 | 372 | 0.010 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2007 | 1091 | 0.010 |
Why?
| | Structure-Activity Relationship | 1 | 2002 | 570 | 0.010 |
Why?
| | Antigen Presentation | 1 | 2002 | 218 | 0.010 |
Why?
| | Cytokines | 1 | 2008 | 2085 | 0.010 |
Why?
| | Ligands | 1 | 2002 | 664 | 0.010 |
Why?
| | Transfection | 1 | 2002 | 945 | 0.010 |
Why?
| | RNA, Messenger | 1 | 2007 | 2833 | 0.010 |
Why?
| | Blotting, Western | 1 | 2002 | 1226 | 0.010 |
Why?
| | Protein Conformation | 1 | 2002 | 934 | 0.010 |
Why?
| | Amino Acids | 1 | 2002 | 497 | 0.010 |
Why?
| | Models, Molecular | 1 | 2002 | 1570 | 0.010 |
Why?
| | Vincristine | 1 | 1997 | 116 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 1997 | 247 | 0.010 |
Why?
| | B-Lymphocytes | 1 | 2002 | 847 | 0.010 |
Why?
| | Remission Induction | 1 | 1997 | 288 | 0.010 |
Why?
| | Peptides | 1 | 2002 | 985 | 0.010 |
Why?
| | Protein Binding | 1 | 2002 | 2224 | 0.010 |
Why?
| | Doxorubicin | 1 | 1997 | 362 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1997 | 1353 | 0.010 |
Why?
|
|
Schenk's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|